Exact Sciences Corp
WHO'M
ai
Digital Profiler. Einfach den AI-Button klicken
FIGI: BBG000CNDF89
EXAS
Exact Sciences Corp
GICS: 35201010
·
Sektor: Healthcare
·
Sub-Sektor: Diagnostics & Research
NAME
Exact Sciences Corp
ISIN
US30063P1057
TICKER
EXAS
MIC
XNAS
REUTERS
EXAS.OQ
BLOOMBERG
EXAS US
F&G:
63
Financial Intelligence
FÜR INVESTOREN
FÜR TRADER
Börsenhandel
Der X-News Explorer ist die ultimative Informationsquelle für börsenaffine Anleger, die sich schnell und komfortabel einen Überblick über die aktuelle Nachrichtenlage eines börsennotierten Unternehmens verschaffen möchten. Ihnen stehen hier verschiedene Newswire-Services zur Verfügung. Wird ein News-Alert angezeigt, liegen Unternehmensnachrichten vor, die Sie möglicherweise interessieren könnten. Dieser Service wird Ihnen von BusinessWire bereitgestellt.
Do., 31.07.2025
Exact Sciences
US30063P1057
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced an expanded partnership with Humana Inc. to enhance access to colorectal cancer (CRC) screening.
Through the partnership, the Cologuard Plus™ test will be available as an in-network service for eligible Humana Medicare Advantage memb...
Exact Sciences
Mo., 14.07.2025
Exact Sciences
US30063P1057
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2025 financial results after the close of the U.S. financial markets on August 6, 2025. Following the release, company management will host a webcast and conference call at 5 p.m. ET...
Exact Sciences
Mi., 09.07.2025
Exact Sciences
US30063P1057
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that its Oncodetect™ molecular residual disease (MRD) test has received Medicare coverage through the Centers for Medicare & Medicaid Services’ (CMS) Molecular Diagnostic Services Program (MolDX) for serial use in patients with sta...
Exact Sciences
Mi., 28.05.2025
Exact Sciences
US30063P1057
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced new data to be presented from the Beta-CORRECT clinical validation study at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Results from Beta-CORRECT, a subset of the GALAXY cohort, validate the performance of its...
Exact Sciences
Di., 27.05.2025
Exact Sciences
US30063P1057
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast.
William Blair 45th Annual Growth Stock Conference, Chicago
Presentation on Tuesday, June 3, 2025 at 9:40 a.m. ET
...
Exact Sciences
Do., 22.05.2025
Exact Sciences
US30063P1057
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it will present ten abstracts at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30–June 3, 2025, in Chicago, Ill. Presentations include new data on the Oncodetect™ molecular residual disease (MRD...
Exact Sciences
Mo., 12.05.2025
Exact Sciences
US30063P1057
Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today that it has been certified as a 2025 Great Place To Work® for the seventh consecutive year in the U.S., and for the first time in the U.K., Japan, Canada, France, Italy, Poland, and Germany.
The recognition is based on a confidential survey...
Exact Sciences
Fr., 02.05.2025
Exact Sciences
US30063P1057
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast.
BofA Securities Health Care Conference, Las Vegas
Fireside chat on Wednesday, May 14, 2025 at 1:40 p.m. ET (10:40 a...
Exact Sciences
Do., 01.05.2025
Exact Sciences
US30063P1057
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $707 million for the first quarter ended March 31, 2025, compared to $638 million for the same period of 2024.
“Our strong first quarter results pave the way for 2025 to mark our most transformati...
Exact Sciences
Di., 29.04.2025
Exact Sciences
US30063P1057
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the company will present 15 abstracts during Digestive Disease Week (DDW) 2025, taking place May 3-6, 2025, in San Diego, California. The abstracts demonstrate high adherence and strong predicted preference for the Cologuard® test alon...
Exact Sciences
Informationen zu Product Placements
BARRISTA SMART * AD
P R O D U C T S U G G E S T I O N S
